William J. Catalona
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William J. Catalona has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Stacy Loeb
Department of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs, New York, NY
29 shared publications Donghui Kan
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
17 shared publicationsBrian T. Helfand
Department of Surgery, Division of Urology, John and Carol Walter Center for Urological Health, NorthShore University Health System, Evanston, IL, USA
13 shared publicationsKimberly A. Roehl
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, USA
12 shared publicationsBarry B. McGuire
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, USA
6 shared publicationsGustavo F. Carvalhal
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
5 shared publications
Latest Publications
- 26 February 2015
- Published by Springer Nature in Human Genetics
- Vol. 134 (4) , 439-450
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases
Genetic studies have identified single nucleotide polymorphisms (SNPs) associated with the risk of prostate cancer (PC). It remains unclear whether such genetic variants are associated with disease aggressiveness. The NCI-SPORE Genetics Working Group retrospectively collected clinicopathologic information and genotype data for 36 SNPs which at the time had been validated to be associated with PC risk from 25,674 cases with PC. Cases were grouped according to race, Gleason score (Gleason ≤6, 7, ≥8) and aggressiveness (non-aggressive, intermediate, and aggressive disease). Statistical analyses were used to compare the frequency of the SNPs between different disease cohorts. After adjusting for multiple testing, only PC-risk SNP rs2735839 (G) was significantly and inversely associated with aggressive (OR = 0.77; 95 % CI 0.69–0.87) and high-grade disease (OR = 0.77; 95 % CI 0.68–0.86) in European men. Similar associations with aggressive (OR = 0.72; 95 % CI 0.58–0.89) and high-grade disease (OR = 0.69; 95 % CI 0.54–0.87) were documented in African-American subjects. The G allele of rs2735839 was associated with disease aggressiveness even at low PSA levels (<4.0 ng/mL) in both European and African-American men. Our results provide further support that a PC-risk SNP rs2735839 near the KLK3 gene on chromosome 19q13 may be associated with aggressive and high-grade PC. Future prospectively designed, case-case GWAS are needed to identify additional SNPs associated with PC aggressiveness.
- 26 February 2015
- Published by Springer Nature in Human Genetics
- Vol. 134 (4) , 439-450
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases
Genetic studies have identified single nucleotide polymorphisms (SNPs) associated with the risk of prostate cancer (PC). It remains unclear whether such genetic variants are associated with disease aggressiveness. The NCI-SPORE Genetics Working Group retrospectively collected clinicopathologic information and genotype data for 36 SNPs which at the time had been validated to be associated with PC risk from 25,674 cases with PC. Cases were grouped according to race, Gleason score (Gleason ≤6, 7, ≥8) and aggressiveness (non-aggressive, intermediate, and aggressive disease). Statistical analyses were used to compare the frequency of the SNPs between different disease cohorts. After adjusting for multiple testing, only PC-risk SNP rs2735839 (G) was significantly and inversely associated with aggressive (OR = 0.77; 95 % CI 0.69–0.87) and high-grade disease (OR = 0.77; 95 % CI 0.68–0.86) in European men. Similar associations with aggressive (OR = 0.72; 95 % CI 0.58–0.89) and high-grade disease (OR = 0.69; 95 % CI 0.54–0.87) were documented in African-American subjects. The G allele of rs2735839 was associated with disease aggressiveness even at low PSA levels (<4.0 ng/mL) in both European and African-American men. Our results provide further support that a PC-risk SNP rs2735839 near the KLK3 gene on chromosome 19q13 may be associated with aggressive and high-grade PC. Future prospectively designed, case-case GWAS are needed to identify additional SNPs associated with PC aggressiveness.
- Open Access
- 1 October 2014
- Published by Elsevier in Asian Journal of Urology
- Vol. 1 (1) , 12-14
History of the discovery and clinical translation of prostate-specific antigen
- 1 October 2014
- Published by Elsevier in Asian Journal of Urology
- Vol. 1 (1) , 12-14
Open AccessHistory of the discovery and clinical translation of prostate-specific antigen
- Open Access
- 27 January 2014
- Published by Wiley in BJU International
- Vol. 114 (6b) , E50-E55
Genetically adjusted prostate‐specific antigen values may prevent delayed biopsies in A frican‐ A merican men
Objective: To evaluate whether genetic correction using the genetic variants prostate‐specific antigen ( PSA )‐single nucleotide polymorphisms ( SNPs ) could reduce potentially unnecessary and/or delayed biopsies in A frican‐ A merican men. Subjects and Methods: We compared the genotypes of four PSA ‐ SNPs between 964 C aucasian and 363 A frican‐ A merican men without known prostate cancer ( PCa ). We adjusted the PSA values based on an individual's PSA‐SNP carrier status, and calculated the percentage of men that would meet commonly used PSA thresholds for biopsy (≥2.5 or ≥4.0 ng/mL) before and after genetic correction. Potentially unnecessary and delayed biopsies were defined as those men who were below and above the biopsy threshold after genetic correction, respectively. Results: Overall, 349 (96.1%) and 354 (97.5%) A frican‐ A merican men had measured PSA levels P < 0.001) reduction in potentially delayed biopsies by 2.5% and 3.9%, based on the biopsy threshold level. Conclusions: There are significant differences in the influence of the PSA ‐ SNPs between A frican‐ A merican and C aucasian men without known PCa , as genetic correction resulted in an increased proportion of A frican‐ A merican men crossing the threshold for biopsy. These results raise the question of whether genetic differences in PSA might contribute to delayed PCa diagnosis in A frican‐ A merican men.
- 27 January 2014
- Published by Wiley in BJU International
- Vol. 114 (6b) , E50-E55
Open AccessGenetically adjusted prostate‐specific antigen values may prevent delayed biopsies in A frican‐ A merican men
Objective: To evaluate whether genetic correction using the genetic variants prostate‐specific antigen ( PSA )‐single nucleotide polymorphisms ( SNPs ) could reduce potentially unnecessary and/or delayed biopsies in A frican‐ A merican men. Subjects and Methods: We compared the genotypes of four PSA ‐ SNPs between 964 C aucasian and 363 A frican‐ A merican men without known prostate cancer ( PCa ). We adjusted the PSA values based on an individual's PSA‐SNP carrier status, and calculated the percentage of men that would meet commonly used PSA thresholds for biopsy (≥2.5 or ≥4.0 ng/mL) before and after genetic correction. Potentially unnecessary and delayed biopsies were defined as those men who were below and above the biopsy threshold after genetic correction, respectively. Results: Overall, 349 (96.1%) and 354 (97.5%) A frican‐ A merican men had measured PSA levels P < 0.001) reduction in potentially delayed biopsies by 2.5% and 3.9%, based on the biopsy threshold level. Conclusions: There are significant differences in the influence of the PSA ‐ SNPs between A frican‐ A merican and C aucasian men without known PCa , as genetic correction resulted in an increased proportion of A frican‐ A merican men crossing the threshold for biopsy. These results raise the question of whether genetic differences in PSA might contribute to delayed PCa diagnosis in A frican‐ A merican men.
- 16 December 2013
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 6 (2) , 74-77
The Prostate Health Index: a new test for the detection of prostate cancer
A major focus in urologic research is the identification of new biomarkers with improved specificity for clinically-significant prostate cancer. A promising new test based on prostate-specific antigen (PSA) is called the Prostate Health Index (PHI), which has recently been approved in the United States, Europe and Australia. PHI is a mathematical formula that combines total PSA, free PSA and [-2] proPSA. Numerous international studies have consistently shown that PHI outperforms its individual components for the prediction of overall and high-grade prostate cancer on biopsy. PHI also predicts the likelihood of progression during active surveillance, providing another noninvasive modality to potentially select and monitor this patient population. This article reviews the evidence on this new blood test with significant promise for both prostate cancer screening and treatment decision-making.
- 16 December 2013
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 6 (2) , 74-77
The Prostate Health Index: a new test for the detection of prostate cancer
A major focus in urologic research is the identification of new biomarkers with improved specificity for clinically-significant prostate cancer. A promising new test based on prostate-specific antigen (PSA) is called the Prostate Health Index (PHI), which has recently been approved in the United States, Europe and Australia. PHI is a mathematical formula that combines total PSA, free PSA and [-2] proPSA. Numerous international studies have consistently shown that PHI outperforms its individual components for the prediction of overall and high-grade prostate cancer on biopsy. PHI also predicts the likelihood of progression during active surveillance, providing another noninvasive modality to potentially select and monitor this patient population. This article reviews the evidence on this new blood test with significant promise for both prostate cancer screening and treatment decision-making.
- 1 May 2013
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (5) , 1702-1706
Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration
Reported prostate specific antigen values may differ substantially among assays using Hybritech® or WHO standardization. The Beckman Coulter® Prostate Health Index and [-2]proPSA are newly approved serum markers associated with prostate cancer risk and aggressiveness. We studied the influence of assay standardization on these markers. Prostate specific antigen, percent free prostate specific antigen and [-2]proPSA were measured using Hybritech calibration in 892 men from a prospective, multicenter study undergoing prostate biopsy. We calculated the Prostate Health Index using the equation, ([-2]proPSA/free prostate specific antigen) × PSA. Index performance characteristics for prostate cancer detection were then determined using recalculated WHO calibration prostate specific antigen values. The median Prostate Health Index was significantly higher in men with prostate cancer than in those with negative biopsies using WHO values (47.4 vs 39.8, p <0.001). The index offered improved discrimination of prostate cancer detection on biopsy (AUC 0.704) compared to percent free or total prostate specific antigen using the WHO calibration. The Prostate Health Index can be calculated using Hybritech or WHO standardized assays. It significantly improved prediction of the biopsy outcome over that of percent free or prostate specific antigen alone.
- 1 May 2013
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (5) , 1702-1706
Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration
Reported prostate specific antigen values may differ substantially among assays using Hybritech® or WHO standardization. The Beckman Coulter® Prostate Health Index and [-2]proPSA are newly approved serum markers associated with prostate cancer risk and aggressiveness. We studied the influence of assay standardization on these markers. Prostate specific antigen, percent free prostate specific antigen and [-2]proPSA were measured using Hybritech calibration in 892 men from a prospective, multicenter study undergoing prostate biopsy. We calculated the Prostate Health Index using the equation, ([-2]proPSA/free prostate specific antigen) × PSA. Index performance characteristics for prostate cancer detection were then determined using recalculated WHO calibration prostate specific antigen values. The median Prostate Health Index was significantly higher in men with prostate cancer than in those with negative biopsies using WHO values (47.4 vs 39.8, p <0.001). The index offered improved discrimination of prostate cancer detection on biopsy (AUC 0.704) compared to percent free or total prostate specific antigen using the WHO calibration. The Prostate Health Index can be calculated using Hybritech or WHO standardized assays. It significantly improved prediction of the biopsy outcome over that of percent free or prostate specific antigen alone.
- 1 May 2013
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (5) , 1697-1701
Personalized Prostate Specific Antigen Testing Using Genetic Variants May Reduce Unnecessary Prostate Biopsies
Purpose: Recent studies have identified genetic variants associated with increased serum prostate specific antigen concentrations and prostate cancer risk, raising the possibility of diagnostic bia...
- 1 May 2013
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 189 (5) , 1697-1701
Personalized Prostate Specific Antigen Testing Using Genetic Variants May Reduce Unnecessary Prostate Biopsies
Purpose: Recent studies have identified genetic variants associated with increased serum prostate specific antigen concentrations and prostate cancer risk, raising the possibility of diagnostic bia...
- 1 January 2013
- Published by Elsevier in European Urology
- Vol. 63 (1) , 180
Re: Quality-of-life Effects of Prostate-specific Antigen Screening
- 1 January 2013
- Published by Elsevier in European Urology
- Vol. 63 (1) , 180
Re: Quality-of-life Effects of Prostate-specific Antigen Screening
- 1 January 2013
- Published by Elsevier in European Urology
- Vol. 63 (1) , 179
Re: Prostate-specific Antigen Screening for Prostate Cancer and the Risk of Overt Metastatic Disease at Presentation: Analysis of Trends Over Time
- 1 January 2013
- Published by Elsevier in European Urology
- Vol. 63 (1) , 179
Re: Prostate-specific Antigen Screening for Prostate Cancer and the Risk of Overt Metastatic Disease at Presentation: Analysis of Trends Over Time
- 1 December 2012
- Published by Elsevier in European Urology
- Vol. 62 (6) , 1195
Re: Radical Prostatectomy Versus Observation for Localized Prostate Cancer
- 1 December 2012
- Published by Elsevier in European Urology
- Vol. 62 (6) , 1195
Re: Radical Prostatectomy Versus Observation for Localized Prostate Cancer
- 1 September 2012
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 30 (5) , 584-589
External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series
- 1 September 2012
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 30 (5) , 584-589
External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series